SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors digest news of its upcoming Russell 3000 index inclusion and a high-profile partnership with the U.S. Army to develop domestic heavy rare earth processing facilities. While the community is actively debating the company's long-term potential as a defense industry supplier versus concerns over volatility and dilution, traders are closely watching for signs of a short squeeze amid high short interest and institutional accumulation.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong quarterly profitability and upgraded analyst outlooks against geopolitical instability and Middle East shipping disruptions. The community remains focused on the company's long-term production growth and institutional backing, while actively debating the impact of energy sector volatility on its current valuation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors debate the impact of high short interest and institutional manipulation against the brand's long-term growth potential and distribution partnership with Pepsi. The community is actively discussing the stock's recent volatility, comparing its performance to competitors like Monster, and speculating on the potential for a massive squeeze or buyout.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is seeing heightened investor attention as community members debate the timing of clinical trial catalysts and the potential for a strategic partnership, while some traders closely monitor the company's pending financial filings and ongoing volatility. Enthusiasts are focusing on the company's recent operational updates and the broader implications of its immunotherapy trial, while others remain cautious and continue to analyze the stock's tight float and the impact of short-selling pressure.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is trending as shareholders anticipate an upcoming FCC Notice of Proposed Rulemaking (NPRM) regarding the company's spectrum rights, with active community discussion centered on potential national security catalysts and the impact of significant liquidity events like warrant redemptions. Investors are debating the timing of FCC agenda announcements and the influence of heavy institutional positioning against a backdrop of ongoing regulatory hurdles.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors prepare for an upcoming FDA advisory committee meeting and PDUFA date for its Duchenne muscular dystrophy therapy, Deramiocel. The stock faces volatility driven by community debate over the strength of clinical data, patent litigation, and institutional accumulation, with bulls emphasizing strong Phase 3 results as the primary catalyst for a potential rally.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant downward pressure as investors navigate the recent integration of TopBuild and lingering concerns over share dilution, while the community remains divided between long-term bulls betting on Brad Jacobs' track record and frustrated traders wary of continued selling. The stock is a focal point of intense discussion as market participants debate whether the current price action represents a forced liquidation by arbitrageurs or a more fundamental long-term challenge.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing extreme volatility as market participants debate whether recent massive pullbacks represent a genuine buying opportunity or a deeper correction fueled by institutional liquidation. The stock remains a focal point for intense sentiment clashes, with traders divided between betting on a sharp relief bounce and warning of further downside pressure amid broader semiconductor sector jitters.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending as investors reassess the company's growth trajectory following a significant stock price pullback. While the company continues to demonstrate strong fundamentals and a dominant market position, the community is debating whether the current price action reflects a temporary valuation reset or a long-term shift in growth expectations.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending due to a surge in investor confidence driven by rebounding lithium prices, strong demand for battery energy storage, and strategic supply chain shifts. The community is actively discussing its momentum, with many highlighting potential breakouts and long-term recovery prospects as the company benefits from both increased EV adoption and energy infrastructure needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CON vs. MEDP: Which Stock Is the Better Value Option?

Why Medpace (MEDP) Dipped More Than Broader Market Today

Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.

Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.

Medpace Stock Outlook Turns on Backlog Quality and Cancellations

MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.

CON or MEDP: Which Is the Better Value Stock Right Now?

Medpace (MEDP) Advances While Market Declines: Some Information for Investors

Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.

Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights

Medpace (MEDP) closed the most recent trading day at $461.6, moving 1.26% from the previous trading session.

Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

Medpace Holdings, Inc. (Nasdaq: MEDP) (Medpace) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these...

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Medpace Holdings Inc

Kohl’s, Medpace, General Motors, Lockheed Martin, Northrop Grumman: Stocks Making The Biggest Moves Today

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$537.73
Prev Close	$537.92
Open	$529.99
Dividend Yield	0.00%
50-Day Moving Average	$472.56
Beta	1.11
Avg. Volume	306,216.34
PE Ratio	33.84

52-Week High	$628.92
52-Week Low	$306.70
Market Capitalization	$15.36B
EPS (Annual)	$15.28
Price to Book	25.61
Revenue Per Employee	$408,102.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

MEDPMedpace Holdings Inc

Latest MEDP News